Plant Name: Rhaponticum carthamoides
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| ADRA2B; HTR1E; HTR7; ADRA1A; ADRA2C; ADRB2; ADRB3; ADRA1D; ADRA2A; HTR5A; DRD2; HTR4; HTR1F; HTR1B; HTR1D; ADORA3; DRD3; HTR2B; HTR2A; HTR1A; HTR2C; HTR6; | |
| TSHR; OPRK1; OPRD1; OPRM1; | |
| GABBR1; | |
| TDP1; BLM; PKM; HSD17B1; MPO; HSD17B10; NOX4; ALOX15; USP2; TNKS; TNKS2; | |
| ACHE; | |
| HTR3A; | |
| GABRR1; | |
| CFTR; | |
| GSK3B; SYK; FLT3; MAPK1; CDK6; CSNK2A1; | |
| AR; | |
| ESR2; ESR1; | |
| KDM4E; | |
| MAOA; PTGS2; XDH; | |
| HIF1A; TP53; | |
| KMT2A; | |
| ABCB1; ABCC1; ABCG2; | |
| SLC6A11; SLC6A4; SLC6A1; SLCO1B3; SLCO1B1; | |
| RAB9A; LMNA; NPC1; MAPT; THPO; TTR; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| 5HT3 receptor | HTR3A | Serotonin 3a (5-HT3a) receptor | P46098 | CHEMBL1899 |
| ATP-binding cassette | ABCB1 | P-glycoprotein 1 | P08183 | CHEMBL4302 |
| ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
| ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
| Chloride channel | CFTR | Cystic fibrosis transmembrane conductance regulator | P13569 | CHEMBL4051 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 2 | CYP2A6 | Cytochrome P450 2A6 | P11509 | CHEMBL5282 |
| Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
| Enzyme_unclassified | PKM | Pyruvate kinase isozymes M1/M2 | P14618 | CHEMBL1075189 |
| Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
| Enzyme_unclassified | MPO | Myeloperoxidase | P05164 | CHEMBL2439 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
| Enzyme_unclassified | TNKS | Tankyrase-1 | O95271 | CHEMBL6164 |
| Enzyme_unclassified | TNKS2 | Tankyrase-2 | Q9H2K2 | CHEMBL6154 |
| GABA-A receptor | GABRR1 | GABA receptor rho-1 subunit | P24046 | CHEMBL3561 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
| Nuclear hormone receptor subfamily 3 group C | AR | Androgen Receptor | P10275 | CHEMBL1871 |
| Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
| Oxidoreductase | PTGS2 | Cyclooxygenase-2 | P35354 | CHEMBL230 |
| Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Peptide receptor (family A GPCR) | OPRK1 | Kappa opioid receptor | P41145 | CHEMBL237 |
| Peptide receptor (family A GPCR) | OPRD1 | Delta opioid receptor | P41143 | CHEMBL236 |
| Peptide receptor (family A GPCR) | OPRM1 | Mu opioid receptor | P35372 | CHEMBL233 |
| Plant homeodomain | KMT2A | Histone-lysine N-methyltransferase MLL | Q03164 | CHEMBL1293299 |
| Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
| Protein Kinase | SYK | Tyrosine-protein kinase SYK | P43405 | CHEMBL2599 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Kinase | CDK6 | Cyclin-dependent kinase 6 | Q00534 | CHEMBL2508 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| SLC superfamily of solute carriers | SLC6A11 | GABA transporter 3 | P48066 | CHEMBL5208 |
| SLC superfamily of solute carriers | SLC6A4 | Serotonin transporter | P31645 | CHEMBL228 |
| SLC superfamily of solute carriers | SLC6A1 | GABA transporter 1 | P30531 | CHEMBL1903 |
| SLC superfamily of solute carriers | SLCO1B3 | Solute carrier organic anion transporter family member 1B3 | Q9NPD5 | CHEMBL1743121 |
| SLC superfamily of solute carriers | SLCO1B1 | Solute carrier organic anion transporter family member 1B1 | Q9Y6L6 | CHEMBL1697668 |
| Small molecule receptor (family A GPCR) | ADRA2B | Alpha-2b adrenergic receptor | P18089 | CHEMBL1942 |
| Small molecule receptor (family A GPCR) | HTR1E | Serotonin 1e (5-HT1e) receptor | P28566 | CHEMBL2182 |
| Small molecule receptor (family A GPCR) | HTR7 | Serotonin 7 (5-HT7) receptor | P34969 | CHEMBL3155 |
| Small molecule receptor (family A GPCR) | ADRA1A | Alpha-1a adrenergic receptor | P35348 | CHEMBL229 |
| Small molecule receptor (family A GPCR) | ADRA2C | Alpha-2c adrenergic receptor | P18825 | CHEMBL1916 |
| Small molecule receptor (family A GPCR) | ADRB2 | Beta-2 adrenergic receptor | P07550 | CHEMBL210 |
| Small molecule receptor (family A GPCR) | ADRB3 | Beta-3 adrenergic receptor | P13945 | CHEMBL246 |
| Small molecule receptor (family A GPCR) | ADRA1D | Alpha-1d adrenergic receptor | P25100 | CHEMBL223 |
| Small molecule receptor (family A GPCR) | ADRA2A | Alpha-2a adrenergic receptor | P08913 | CHEMBL1867 |
| Small molecule receptor (family A GPCR) | HTR5A | Serotonin 5a (5-HT5a) receptor | P47898 | CHEMBL3426 |
| Small molecule receptor (family A GPCR) | DRD2 | Dopamine D2 receptor | P14416 | CHEMBL217 |
| Small molecule receptor (family A GPCR) | HTR4 | Serotonin 4 (5-HT4) receptor | Q13639 | CHEMBL1875 |
| Small molecule receptor (family A GPCR) | HTR1F | Serotonin 1f (5-HT1f) receptor | P30939 | CHEMBL1805 |
| Small molecule receptor (family A GPCR) | HTR1B | Serotonin 1b (5-HT1b) receptor | P28222 | CHEMBL1898 |
| Small molecule receptor (family A GPCR) | HTR1D | Serotonin 1d (5-HT1d) receptor | P28221 | CHEMBL1983 |
| Small molecule receptor (family A GPCR) | ADORA3 | Adenosine A3 receptor | P0DMS8 | CHEMBL256 |
| Small molecule receptor (family A GPCR) | DRD3 | Dopamine D3 receptor | P35462 | CHEMBL234 |
| Small molecule receptor (family A GPCR) | HTR2B | Serotonin 2b (5-HT2b) receptor | P41595 | CHEMBL1833 |
| Small molecule receptor (family A GPCR) | HTR2A | Serotonin 2a (5-HT2a) receptor | P28223 | CHEMBL224 |
| Small molecule receptor (family A GPCR) | HTR1A | Serotonin 1a (5-HT1a) receptor | P08908 | CHEMBL214 |
| Small molecule receptor (family A GPCR) | HTR2C | Serotonin 2c (5-HT2c) receptor | P28335 | CHEMBL225 |
| Small molecule receptor (family A GPCR) | HTR6 | Serotonin 6 (5-HT6) receptor | P50406 | CHEMBL3371 |
| Small molecule receptor (family C GPCR) | GABBR1 | GABA-B receptor 1 | Q9UBS5 | CHEMBL2064 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
| Unclassified | TTR | Transthyretin | P02766 | CHEMBL3194 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0051379; epinephrine binding | 5.581E-11 | 1.192E-08 | ADRA2A, ADRA2B, ADRA2C, ADRB2, ADRB3 |
| BP | Unclassified; | GO:0032844; regulation of homeostatic process | 7.232E-11 | 1.529E-08 | ADRA2A, CDK6, CFTR, DRD2, DRD3, HIF1A, HTR2A, HTR2B, HTR2C, MAPK1, NPC1, OPRK1, PTGS2, SYK, TNKS, TNKS2 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 1.119E-10 | 2.321E-08 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2D6, CYP3A4, MPO, NOX4, PTGS2 |
| BP | GO:0009987; cellular process | GO:0007198; adenylate cyclase-inhibiting serotonin receptor signaling pathway | 2.591E-10 | 4.949E-08 | HTR1A, HTR1B, HTR5A, HTR7 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 3.684E-10 | 6.798E-08 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2D6, CYP3A4 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 5.843E-10 | 1.043E-07 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2D6, CYP3A4, NOX4 |
| BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 1.692E-09 | 2.791E-07 | AR, BLM, CFTR, CYP1A1, CYP1B1, ESR1, FLT3, MAPK1, NOX4, NPC1, OPRM1, PTGS2, SLC6A4 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 1.837E-08 | 2.424E-06 | ALOX15, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2D6, CYP3A4, XDH |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 2.805E-08 | 3.551E-06 | CFTR, DRD2, DRD3, HIF1A, MAPK1, NPC1, PTGS2, SYK, TNKS, TNKS2 |
| MF | GO:0060089; molecular transducer activity | GO:0004938; alpha2-adrenergic receptor activity | 6.585E-08 | 7.792E-06 | ADRA2A, ADRA2B, ADRA2C |
| BP | GO:0009987; cellular process | GO:0002031; G-protein coupled receptor internalization | 8.367E-08 | 9.538E-06 | DRD2, DRD3, HTR1B, HTR2B |
| BP | GO:0009987; cellular process | GO:0014059; regulation of dopamine secretion | 9.189E-08 | 1.031E-05 | DRD2, DRD3, HTR1B, HTR2A, OPRK1 |
| CC | GO:0044464; cell part | GO:0042995; cell projection | 1.094E-07 | 1.197E-05 | ADRA2C, CDK6, DRD2, DRD3, GABBR1, HIF1A, HTR2A, HTR2B, HTR3A, HTR5A, HTR6, MAPK1, MAPT, OPRD1, OPRK1, OPRM1, PKM, PTGS2, SLC6A1, SLC6A11, SLC6A4 |
| BP | GO:0009987; cellular process | GO:0070374; positive regulation of ERK1 and ERK2 cascade | 1.105E-07 | 1.203E-05 | ADRA1A, ALOX15, DRD2, HTR2A, HTR2B, HTR2C, NOX4, OPRM1, THPO |
| BP | GO:0065007; biological regulation | GO:0007194; negative regulation of adenylate cyclase activity | 1.859E-07 | 1.883E-05 | ADRA2A, DRD2, DRD3, GABBR1, OPRM1 |
| BP | Unclassified; | GO:0045907; positive regulation of vasoconstriction | 2.184E-07 | 2.181E-05 | ADRA1A, ADRA1D, ADRA2C, HTR2A, PTGS2 |
| BP | GO:0065007; biological regulation | GO:0035625; epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway | 2.626E-07 | 2.564E-05 | ADRA2A, ADRA2B, ADRA2C |
| BP | GO:0009987; cellular process | GO:0032811; negative regulation of epinephrine secretion | 2.626E-07 | 2.564E-05 | ADRA2A, ADRA2B, ADRA2C |
| BP | GO:0008152; metabolic process | GO:0010513; positive regulation of phosphatidylinositol biosynthetic process | 6.546E-07 | 5.818E-05 | HTR2A, HTR2B, HTR2C |
| MF | GO:0005488; binding | GO:0051380; norepinephrine binding | 6.546E-07 | 5.818E-05 | ADRA2A, ADRB2, ADRB3 |
| BP | GO:0007610; behavior | GO:0007626; locomotory behavior | 6.925E-07 | 6.105E-05 | DRD2, DRD3, HTR2C, NPC1, OPRD1, OPRK1, OPRM1, USP2 |
| BP | GO:0008283; cell proliferation | GO:0008285; negative regulation of cell proliferation | 8.901E-07 | 7.722E-05 | ADORA3, ADRA1A, AR, CDK6, CYP1B1, DRD2, KMT2A, LMNA, NOX4, OPRM1, PTGS2, SLC6A4, TP53, XDH |
| BP | GO:0007610; behavior | GO:0048148; behavioral response to cocaine | 1.194E-06 | 9.927E-05 | DRD2, DRD3, HTR2A, OPRK1 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.305E-06 | 1.081E-04 | CYP1A2, CYP2D6, CYP3A4 |
| MF | GO:0005488; binding | GO:0005496; steroid binding | 1.399E-06 | 1.145E-04 | AR, CYP3A4, ESR1, ESR2, HSD17B1, NPC1 |
| BP | GO:0051179; localization | GO:0006869; lipid transport | 1.424E-06 | 1.161E-04 | ABCB1, ABCC1, ABCG2, CFTR, DRD2, DRD3, NPC1, SLCO1B1, SLCO1B3 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.471E-06 | 1.191E-04 | CYP1A1, CYP1A2, CYP1B1, CYP2A6 |
| BP | Unclassified; | GO:0032845; negative regulation of homeostatic process | 2.047E-06 | 1.609E-04 | ADRA2A, DRD2, HTR2A, HTR2B, HTR2C, TNKS, TNKS2 |
| BP | GO:0009987; cellular process | GO:0035690; cellular response to drug | 2.234E-06 | 1.722E-04 | BLM, CDK6, CFTR, CYP1B1, HTR1B, MAPK1, OPRM1, PTGS2, TP53 |
| BP | GO:0008152; metabolic process | GO:0009804; coumarin metabolic process | 2.278E-06 | 1.722E-04 | CYP1A1, CYP2A6, CYP2D6 |
| BP | GO:0009987; cellular process | GO:0014062; regulation of serotonin secretion | 2.278E-06 | 1.722E-04 | HTR1A, HTR1B, SLC6A4 |
| MF | GO:0005215; transporter activity | GO:0008559; xenobiotic transmembrane transporting ATPase activity | 2.278E-06 | 1.722E-04 | ABCB1, ABCC1, ABCG2 |
| BP | GO:0008152; metabolic process | GO:0016579; protein deubiquitination | 2.367E-06 | 1.778E-04 | ADRB2, AR, CFTR, ESR1, HIF1A, TNKS, TNKS2, TP53, USP2 |
| BP | GO:0009987; cellular process | GO:0010700; negative regulation of norepinephrine secretion | 3.633E-06 | 2.569E-04 | ADRA2A, ADRA2B, ADRA2C |
| MF | GO:0060089; molecular transducer activity | GO:0004985; opioid receptor activity | 3.633E-06 | 2.569E-04 | OPRD1, OPRK1, OPRM1 |
| MF | GO:0005488; binding | GO:0042803; protein homodimerization activity | 3.696E-06 | 2.604E-04 | ABCG2, ACHE, ADRA2A, ADRA2C, ADRB2, ADRB3, BLM, DRD2, FLT3, KMT2A, MAPT, PTGS2, SLC6A4, XDH |
| BP | GO:0032502; developmental process | GO:0007568; aging | 4.658E-06 | 3.210E-04 | ADRA1A, ADRB3, CYP1A1, HTR2A, MPO, NOX4, PTGS2, TP53 |
| BP | GO:0007610; behavior | GO:0042755; eating behavior | 4.924E-06 | 3.382E-04 | ADRB3, OPRD1, OPRK1, OPRM1 |
| CC | GO:0032991; macromolecular complex | GO:0043235; receptor complex | 6.571E-06 | 4.362E-04 | ABCG2, ADRA2A, ADRB2, ADRB3, GABBR1, GABRR1, HTR3A, SYK, TSHR |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 7.740E-06 | 5.046E-04 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0051179; localization | GO:0042908; xenobiotic transport | 7.740E-06 | 5.046E-04 | ABCB1, ABCC1, ABCG2 |
| BP | GO:0050896; response to stimulus | GO:0043278; response to morphine | 8.541E-06 | 5.470E-04 | DRD2, DRD3, OPRK1, OPRM1 |
| BP | GO:0050896; response to stimulus | GO:0009611; response to wounding | 8.624E-06 | 5.507E-04 | ACHE, ADORA3, ALOX15, CYP1A1, DRD2, OPRM1, TP53 |
| CC | GO:0044464; cell part | GO:0030424; axon | 1.017E-05 | 6.344E-04 | ADRA2C, DRD2, HTR2A, HTR3A, MAPK1, MAPT, OPRM1, SLC6A1 |
| BP | GO:0032501; multicellular organismal process | GO:0060736; prostate gland growth | 1.061E-05 | 6.565E-04 | AR, CYP19A1, ESR1 |
| BP | GO:0032501; multicellular organismal process | GO:0051930; regulation of sensory perception of pain | 1.095E-05 | 6.715E-04 | ADRA2C, OPRD1, OPRK1, OPRM1 |
| BP | GO:0032501; multicellular organismal process | GO:0045987; positive regulation of smooth muscle contraction | 1.095E-05 | 6.715E-04 | ADRA1A, ADRA1D, ADRA2B, PTGS2 |
| BP | GO:0050896; response to stimulus | GO:0032355; response to estradiol | 1.175E-05 | 7.165E-04 | CYP1A2, ESR1, HTR5A, PTGS2, SLC6A1, SLC6A4 |
| BP | GO:0065007; biological regulation | GO:0043406; positive regulation of MAP kinase activity | 1.236E-05 | 7.495E-04 | ADRA2A, ADRA2B, FLT3, HTR2A, HTR2B, MAPK1, NOX4, SYK |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 1.411E-05 | 8.392E-04 | CYP1A2, CYP2A6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 1.411E-05 | 8.392E-04 | CYP1A2, CYP2D6, CYP3A4 |
| BP | GO:0065007; biological regulation | GO:0007190; activation of adenylate cyclase activity | 1.545E-05 | 9.090E-04 | ADORA3, ADRB2, ADRB3, TSHR |
| BP | GO:0009987; cellular process | GO:0031635; adenylate cyclase-inhibiting opioid receptor signaling pathway | 1.652E-05 | 9.616E-04 | OPRK1, OPRM1 |
| BP | GO:0009987; cellular process | GO:0007208; phospholipase C-activating serotonin receptor signaling pathway | 1.652E-05 | 9.616E-04 | HTR2A, HTR2C |
| MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 1.652E-05 | 9.616E-04 | ESR1, ESR2 |
| MF | GO:0005488; binding | GO:0071886; 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding | 1.652E-05 | 9.616E-04 | HTR2A, HTR2C |
| MF | GO:0005488; binding | GO:0051378; serotonin binding | 2.590E-27 | 1.410E-23 | HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR3A, HTR5A, HTR7 |
| BP | GO:0023052; signaling | GO:0051967; negative regulation of synaptic transmission, glutamatergic | 2.320E-05 | 1.333E-03 | DRD2, HTR1B, HTR2A |
| BP | GO:0051179; localization | GO:0043271; negative regulation of ion transport | 2.440E-05 | 1.394E-03 | ADRA2A, DRD2, DRD3, HTR1B, HTR2A, PTGS2 |
| BP | GO:0050896; response to stimulus | GO:0014074; response to purine-containing compound | 2.970E-05 | 1.646E-03 | CFTR, NOX4, PTGS2, SLC6A1, SLC6A4, TP53 |
| BP | GO:0008152; metabolic process | GO:2000379; positive regulation of reactive oxygen species metabolic process | 3.372E-05 | 1.859E-03 | MAPT, NOX4, PTGS2, TP53, XDH |
| BP | GO:0051179; localization | GO:0051209; release of sequestered calcium ion into cytosol | 3.399E-05 | 1.864E-03 | DRD2, HTR2A, HTR2B, HTR2C |
| BP | GO:0032501; multicellular organismal process | GO:0045986; negative regulation of smooth muscle contraction | 3.548E-05 | 1.932E-03 | ADRA2C, ADRB2, PTGS2 |
| BP | GO:0065007; biological regulation | GO:1904355; positive regulation of telomere capping | 4.296E-05 | 2.293E-03 | MAPK1, TNKS, TNKS2 |
| BP | GO:0007610; behavior | GO:0008542; visual learning | 4.398E-05 | 2.336E-03 | DRD2, DRD3, HIF1A, KMT2A |
| BP | GO:0040007; growth | GO:0045926; negative regulation of growth | 4.581E-05 | 2.421E-03 | ADRB2, ADRB3, ESR2, HIF1A, MPO, SLC6A4, TP53 |
| BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 4.942E-05 | 2.538E-03 | CYP2D6, CYP3A4 |
| BP | GO:0051179; localization | GO:0099039; sphingolipid translocation | 4.942E-05 | 2.538E-03 | ABCB1, ABCC1 |
| BP | GO:0009987; cellular process | GO:0060160; negative regulation of dopamine receptor signaling pathway | 4.942E-05 | 2.538E-03 | DRD2, DRD3 |
| MF | GO:0003824; catalytic activity | GO:0050473; arachidonate 15-lipoxygenase activity | 4.942E-05 | 2.538E-03 | ALOX15, PTGS2 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 4.942E-05 | 2.538E-03 | CYP1A1, CYP3A4 |
| MF | GO:0060089; molecular transducer activity | GO:0004937; alpha1-adrenergic receptor activity | 4.942E-05 | 2.538E-03 | ADRA1A, ADRA1D |
| MF | GO:0005488; binding | GO:0031690; adrenergic receptor binding | 5.140E-05 | 2.620E-03 | ADRA2A, ADRA2C, ADRB3 |
| MF | GO:0005488; binding | GO:0001965; G-protein alpha-subunit binding | 6.086E-05 | 3.068E-03 | HTR2A, HTR2B, OPRM1 |
| BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 6.748E-05 | 3.378E-03 | HIF1A, LMNA, OPRD1, PTGS2, TP53 |
| BP | GO:0007610; behavior | GO:0007613; memory | 7.063E-05 | 3.503E-03 | DRD2, HTR2A, MAPT, PTGS2, SLC6A4 |
| BP | GO:0008152; metabolic process | GO:0044283; small molecule biosynthetic process | 7.509E-05 | 3.666E-03 | ALOX15, CFTR, CYP19A1, CYP1A1, CYP3A4, MPO, PKM, PTGS2, SYK |
| BP | GO:0032501; multicellular organismal process | GO:0032922; circadian regulation of gene expression | 7.543E-05 | 3.666E-03 | DRD2, DRD3, KMT2A, USP2 |
| CC | GO:0044456; synapse part | GO:0043679; axon terminus | 7.543E-05 | 3.666E-03 | ADRA2C, DRD2, OPRD1, OPRK1 |
| BP | GO:0009987; cellular process | GO:0030168; platelet activation | 8.811E-05 | 4.216E-03 | ADRA2A, ADRA2B, ADRA2C, MAPK1, SYK |
| MF | GO:0005488; binding | GO:0042923; neuropeptide binding | 9.587E-05 | 4.558E-03 | OPRD1, OPRK1, OPRM1 |
| BP | GO:0065007; biological regulation | GO:0001994; norepinephrine-epinephrine vasoconstriction involved in regulation of systemic arterial blood pressure | 9.857E-05 | 4.596E-03 | ADRA1A, ADRA1D |
| BP | GO:0008152; metabolic process | GO:0070213; protein auto-ADP-ribosylation | 9.857E-05 | 4.596E-03 | TNKS, TNKS2 |
| BP | GO:0051179; localization | GO:1901529; positive regulation of anion channel activity | 9.857E-05 | 4.596E-03 | ABCB1, CFTR |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 9.857E-05 | 4.596E-03 | CYP1A1, CYP1A2 |
| BP | GO:0032501; multicellular organismal process | GO:0014827; intestine smooth muscle contraction | 9.857E-05 | 4.596E-03 | HTR1D, HTR2B |
| MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 9.857E-05 | 4.596E-03 | ESR1, ESR2 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 9.857E-05 | 4.596E-03 | CYP1A2, CYP3A4 |
| MF | GO:0005215; transporter activity | GO:0005332; gamma-aminobutyric acid:sodium symporter activity | 9.857E-05 | 4.596E-03 | SLC6A1, SLC6A11 |
| BP | GO:0009987; cellular process | GO:0071396; cellular response to lipid | 1.028E-04 | 4.732E-03 | AR, CDK6, CFTR, ESR1, FLT3, NPC1, OPRK1, SLC6A4 |
| CC | GO:0044464; cell part | GO:0043204; perikaryon | 1.087E-04 | 4.985E-03 | DRD2, HTR5A, MAPK1, OPRK1, OPRM1 |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 1.099E-04 | 5.029E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0065007; biological regulation | GO:0007202; activation of phospholipase C activity | 1.253E-04 | 5.601E-03 | ADRA1A, HTR2A, HTR2B |
| CC | Unclassified; | GO:0120111; neuron projection cytoplasm | 1.367E-04 | 6.073E-03 | HIF1A, MAPK1, MAPT, OPRM1 |
| BP | GO:0023052; signaling | GO:0050806; positive regulation of synaptic transmission | 1.382E-04 | 6.128E-03 | ADRA1A, ADRB2, DRD2, MAPK1, PTGS2 |
| BP | GO:0008152; metabolic process | GO:0006706; steroid catabolic process | 1.600E-04 | 6.980E-03 | CYP19A1, CYP1A2, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0071502; cellular response to temperature stimulus | 1.638E-04 | 7.010E-03 | HTR1B, HTR2B |
| BP | GO:0040011; locomotion | GO:0090325; regulation of locomotion involved in locomotory behavior | 1.638E-04 | 7.010E-03 | DRD2, DRD3 |
| MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 1.638E-04 | 7.010E-03 | CYP1A1, CYP3A4 |
| CC | GO:0044464; cell part | GO:0032838; plasma membrane bounded cell projection cytoplasm | 1.633E-04 | 7.010E-03 | HIF1A, MAPK1, MAPT, OPRM1 |
| BP | GO:0032501; multicellular organismal process | GO:0010575; positive regulation of vascular endothelial growth factor production | 1.794E-04 | 7.572E-03 | CYP1B1, HIF1A, PTGS2 |
| BP | GO:0050896; response to stimulus | GO:2001025; positive regulation of response to drug | 1.794E-04 | 7.572E-03 | DRD2, KMT2A, OPRK1 |
| BP | GO:0065007; biological regulation | GO:0051090; regulation of DNA binding transcription factor activity | 1.855E-04 | 7.797E-03 | ADORA3, AR, CYP1B1, ESR1, ESR2, MAPK1, OPRD1, SYK |
| BP | GO:0032501; multicellular organismal process | GO:2000026; regulation of multicellular organismal development | 1.897E-04 | 7.943E-03 | ADRA2B, ADRA2C, ADRB2, AR, CDK6, CYP1B1, DRD2, DRD3, ESR1, GSK3B, HIF1A, KMT2A, MAPT, OPRM1, PTGS2, SLC6A4, SYK, THPO, XDH |
| MF | GO:0005488; binding | GO:0002039; p53 binding | 1.936E-04 | 8.075E-03 | BLM, GSK3B, HIF1A, TP53 |
| BP | GO:0009987; cellular process | GO:0050873; brown fat cell differentiation | 2.004E-04 | 8.296E-03 | ADRB2, ADRB3, PTGS2 |
| BP | GO:0008152; metabolic process | GO:0042417; dopamine metabolic process | 2.004E-04 | 8.296E-03 | DRD2, DRD3, MAOA |
| BP | GO:0008152; metabolic process | GO:0008209; androgen metabolic process | 2.004E-04 | 8.296E-03 | CYP19A1, CYP3A4, ESR1 |
| CC | GO:0016020; membrane | GO:0005901; caveola | 2.045E-04 | 8.434E-03 | ADRA1A, HTR2A, MAPK1, PTGS2 |
| BP | GO:0051179; localization | GO:0051590; positive regulation of neurotransmitter transport | 2.228E-04 | 9.070E-03 | DRD2, SLC6A1, SLC6A4 |
| BP | GO:0023052; signaling | GO:0032229; negative regulation of synaptic transmission, GABAergic | 2.451E-04 | 9.848E-03 | HTR1B, SLC6A1 |
| BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 2.451E-04 | 9.848E-03 | CYP1A1, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0007210; serotonin receptor signaling pathway | 2.374E-23 | 4.699E-20 | HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR4, HTR5A, HTR6, HTR7 |
| MF | GO:0060089; molecular transducer activity | GO:0004993; G-protein coupled serotonin receptor activity | 2.374E-23 | 4.699E-20 | HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR4, HTR5A, HTR6, HTR7 |
| CC | GO:0044425; membrane part | GO:0005887; integral component of plasma membrane | 1.242E-21 | 1.932E-18 | ABCC1, ADORA3, ADRA1A, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB2, ADRB3, CFTR, DRD2, DRD3, FLT3, GABBR1, GABRR1, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR4, HTR5A, HTR6, HTR7, NPC1, OPRD1, OPRK1, OPRM1, SLC6A1, SLC6A11, SLC6A4, SLCO1B1, SLCO1B3, TSHR |
| MF | Unclassified; | GO:0004872; receptor activity | 3.154E-17 | 2.289E-14 | ADORA3, ADRA1A, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB2, ADRB3, AR, DRD2, DRD3, ESR1, ESR2, FLT3, GABBR1, GABRR1, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR3A, HTR4, HTR5A, HTR6, HTR7, NPC1, OPRD1, OPRK1, OPRM1, TSHR |
| MF | Unclassified; | GO:0099600; transmembrane receptor activity | 4.310E-16 | 2.346E-13 | ADORA3, ADRA1A, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB2, ADRB3, DRD2, DRD3, FLT3, GABBR1, GABRR1, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR4, HTR5A, HTR6, HTR7, NPC1, OPRD1, OPRK1, OPRM1, TSHR |
| BP | GO:0009987; cellular process | GO:0071880; adenylate cyclase-activating adrenergic receptor signaling pathway | 6.584E-15 | 2.867E-12 | ADRA1A, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB2, ADRB3, DRD2 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa04080 | Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | 2.312E-32 | 3.883E-30 | OPRD1; HTR2B; HTR2C; ADRA1D; ADRB2; HTR2A; HTR4; ADRA1A; HTR6; GABRR1; HTR7; ADORA3; DRD2; DRD3; GABBR1; HTR1E; HTR1F; HTR1D; HTR1A; HTR1B; OPRK1; OPRM1; HTR5A; ADRA2C; ADRA2B; ADRA2A; TSHR; ADRB3 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 2.224E-26 | 1.868E-24 | HTR1E; HTR1F; MAOA; HTR1D; ALOX15; HTR1A; HTR2B; HTR1B; HTR2C; HTR3A; HTR2A; HTR5A; HTR4; PTGS2; SLC6A4; HTR6; HTR7; CYP2D6; MAPK1 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 9.380E-13 | 5.253E-11 | GABBR1; HTR1E; HTR1F; HTR1D; HTR1A; HTR1B; ADRB2; HTR4; TSHR; HTR6; MAPK1; DRD2; CFTR |
| hsa04020 | Calcium signaling pathway_Homo sapiens_hsa04020 | 1.227E-10 | 5.153E-09 | HTR6; HTR7; ADRB3; HTR2B; HTR2C; ADRA1D; ADRB2; HTR2A; HTR5A; HTR4; ADRA1A |
| hsa04022 | cGMP-PKG signaling pathway_Homo sapiens_hsa04022 | 1.103E-09 | 3.705E-08 | OPRD1; ADRB3; ADORA3; MAPK1; ADRA1D; ADRB2; ADRA2C; ADRA2B; ADRA1A; ADRA2A |
| hsa04742 | Taste transduction_Homo sapiens_hsa04742 | 3.732E-08 | 1.045E-06 | GABBR1; HTR1E; HTR1F; HTR1D; HTR1A; HTR1B; HTR3A |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 1.076E-07 | 2.583E-06 | HSD17B1; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP19A1 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 4.319E-07 | 8.062E-06 | CYP2A6; CYP2D6; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 3.656E-07 | 7.678E-06 | SLCO1B1; ABCB1; SLCO1B3; CYP3A4; CFTR; ABCG2 |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 1.559E-06 | 2.183E-05 | HSD17B1; CYP1A1; CYP1B1; PTGS2; CYP19A1 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 8.637E-07 | 1.319E-05 | CYP2A6; CYP1A2; CYP1A1; CYP1B1; CYP3A4; PTGS2 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 6.745E-06 | 8.716E-05 | PKM; FLT3; MAPK1; TP53; HIF1A |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 7.801E-06 | 9.361E-05 | CYP2A6; MAOA; CYP2D6; CYP1A2; CYP3A4 |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 4.527E-05 | 4.225E-04 | GABBR1; MAPK1; OPRM1; ESR1; ESR2 |
| hsa04540 | Gap junction_Homo sapiens_hsa04540 | 2.565E-05 | 2.682E-04 | HTR2B; HTR2C; MAPK1; HTR2A; DRD2 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 1.714E-04 | 1.208E-03 | AR; GSK3B; CDK6; FLT3; MAPK1; PTGS2; HIF1A; TP53 |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 1.849E-05 | 2.071E-04 | MAOA; CYP1A2; CYP1A1; CYP1B1 |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 1.045E-04 | 8.774E-04 | GSK3B; MAPK1; TP53; ESR1; HIF1A |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 7.085E-05 | 6.264E-04 | ADRB3; ADRB2; PTGS2; TSHR |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 1.725E-04 | 1.208E-03 | ABCC1; CDK6; ABCB1; CYP1B1; MAPK1; PTGS2; TP53 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 1.131E-04 | 9.046E-04 | OPRD1; ABCC1; ADORA3; MAPK1; TP53 |
| hsa02010 | ABC transporters_Homo sapiens_hsa02010 | 2.714E-05 | 2.682E-04 | ABCC1; ABCB1; CFTR; ABCG2 |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 2.033E-04 | 1.265E-03 | GSK3B; CDK6; CSNK2A1; RAB9A; TP53 |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 1.892E-04 | 1.265E-03 | GSK3B; MAPK1; ESR1; ESR2 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 1.271E-04 | 9.708E-04 | CYP2A6; CYP1A2; CYP1A1; CYP3A4 |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 4.268E-04 | 2.390E-03 | GSK3B; AR; MAPK1; TP53 |
| hsa04727 | GABAergic synapse_Homo sapiens_hsa04727 | 4.088E-04 | 2.390E-03 | GABBR1; GABRR1; SLC6A11; SLC6A1 |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 1.314E-03 | 6.687E-03 | CDK6; PKM; SYK; MAPK1; TP53 |
| hsa04970 | Salivary secretion_Homo sapiens_hsa04970 | 4.268E-04 | 2.390E-03 | ADRB3; ADRA1D; ADRB2; ADRA1A |
| hsa04728 | Dopaminergic synapse_Homo sapiens_hsa04728 | 1.708E-03 | 8.200E-03 | GSK3B; MAOA; DRD2; DRD3 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 3.285E-03 | 1.284E-02 | CYP2A6; PKM; MAOA; HSD17B1; CYP1A2; ALOX15; CYP1A1; PTGS2; CYP3A4; CYP19A1; HSD17B10; XDH |
| hsa04261 | Adrenergic signaling in cardiomyocytes_Homo sapiens_hsa04261 | 2.814E-03 | 1.182E-02 | MAPK1; ADRA1D; ADRB2; ADRA1A |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 1.140E-03 | 5.987E-03 | GSK3B; MAPK1; TP53 |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 1.414E-03 | 6.988E-03 | CDK6; MAPK1; TP53 |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 2.173E-03 | 9.865E-03 | CDK6; MAPK1; TP53 |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 4.426E-03 | 1.690E-02 | GSK3B; MAPK1; MAPT; HSD17B10 |
| hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 1.897E-03 | 8.853E-03 | GSK3B; MAPK1; TP53 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 2.270E-03 | 1.003E-02 | CDK6; MAPK1; TP53 |
| hsa05218 | Melanoma_Homo sapiens_hsa05218 | 2.795E-03 | 1.182E-02 | CDK6; MAPK1; TP53 |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 3.024E-03 | 1.210E-02 | GSK3B; SYK; MAPK1 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 3.024E-03 | 1.210E-02 | CDK6; MAPK1; TP53 |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 5.642E-03 | 2.017E-02 | KMT2A; FLT3; TP53; MPO |
| hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 8.417E-03 | 2.714E-02 | GSK3B; SYK; CSNK2A1; TP53 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 8.561E-03 | 2.714E-02 | MAPK1; TP53; HIF1A; ESR1 |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 1.128E-02 | 3.493E-02 | GSK3B; CDK6; SYK; MAPK1; TP53 |
| hsa04750 | Inflammatory mediator regulation of TRP channels_Homo sapiens_hsa04750 | 6.893E-03 | 2.316E-02 | HTR2B; HTR2C; HTR2A |
| hsa05032 | Morphine addiction_Homo sapiens_hsa05032 | 5.615E-03 | 2.017E-02 | GABBR1; GABRR1; OPRM1 |
| hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 4.797E-03 | 1.791E-02 | CDK6; PTGS2; TP53 |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 7.968E-04 | 4.318E-03 | CYP2A6; CYP3A4; XDH |
| hsa04723 | Retrograde endocannabinoid signaling_Homo sapiens_hsa04723 | 7.489E-03 | 2.467E-02 | GABRR1; MAPK1; PTGS2 |
| hsa04064 | NF-kappa B signaling pathway_Homo sapiens_hsa04064 | 5.964E-03 | 2.045E-02 | SYK; CSNK2A1; PTGS2 |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 1.197E-02 | 3.527E-02 | GSK3B; MAPK1; TP53 |
| hsa04270 | Vascular smooth muscle contraction_Homo sapiens_hsa04270 | 1.197E-02 | 3.527E-02 | MAPK1; ADRA1D; ADRA1A |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 1.803E-02 | 4.886E-02 | LMNA; MAPK1; TP53 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 1.575E-02 | 4.409E-02 | GSK3B; MAPK1; TP53 |
| hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 1.307E-02 | 3.785E-02 | GSK3B; CDK6; TP53 |
| hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 1.872E-02 | 4.991E-02 | GSK3B; CSNK2A1; TP53 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 2.013E-04 | 1.265E-03 | CYP1A2; ALOX15; CYP3A4 |
| hsa04930 | Type II diabetes mellitus_Homo sapiens_hsa04930 | 1.545E-02 | 4.400E-02 | PKM; MAPK1 |
| hsa05030 | Cocaine addiction_Homo sapiens_hsa05030 | 1.607E-02 | 4.425E-02 | MAOA; DRD2 |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 1.143E-02 | 3.493E-02 | MAPK1; TP53 |
| hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 5.837E-03 | 2.043E-02 | MAPK1; TP53 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 5.898E-07 | 9.909E-06 | CYP2A6; CYP1A2; XDH |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | HTR1A; ADRA1D; ADRA1A; ADRA2C; ADRB2; ADRB3; DRD2; DRD2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperprolactinemia | E22.1 | DRD2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Moderate-to-severe acute pain | R52, G89 | OPRM1 |
| J00-J99: Diseases of the respiratory system | Chronic breathing disorders | J44-J47 | ADRB2 |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE |
| NA: NA | Bradycardia | NA | ADRB2 |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | ESR1 |
| O00-O9A: Pregnancy, childbirth and the puerperium | Premature labour | O60.1, P07.3 | ADRB2 |
| NA: NA | Primary insomnia | NA | HTR2C |
| N00-N99: Diseases of the genitourinary system | Prostate hyperplasia | N40 | AR; ADRA1D; ADRA1A |
| C00-D49: Neoplasms | Prostate cancer | C61 | AR; AR; FLT3; ADRA1A; ESR1 |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1; ADRA1D; ADRA1A |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Systemic pain | R52, G89 | OPRM1 |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Huntington's disease | F02.2, G10 | DRD2 |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | SYK |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | OPRM1; PTGS2; SLC6A4 |
| K00-K95: Diseases of the digestive system | Alcoholic hepatitis | K70.1 | AR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Bipolar disorder | F31, F40-F42 | OPRK1; DRD2; DRD2; DRD2; DRD2 |
| C00-D49: Neoplasms | Bladder cancer | C67 | AR; CYP19A1 |
| N00-N99: Diseases of the genitourinary system | Benign prostatic hyperplasia | N40 | ADRA1D; ADRA1A; ADRA1A |
| C00-D49: Neoplasms | B-cell lymphoma | C85.1 | SYK |
| NA: NA | Benign prostatic hypertrophy | NA | DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychiatric disorder | F01-F99 | HTR1A; HTR2A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | HTR1A; HTR1B; DRD2; DRD3; HTR2C |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A; HTR2B |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1 |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ABCB1; ESR1 |
| NA: NA | Addiction | NA | HTR2A |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | ADRA2C |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | OPRM1 |
| NA: NA | GIST | NA | FLT3 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ADORA3; ADRA1D; HTR2A; ADRA1A; ACHE; ADRA2C; ADRB3; DRD2 |
| NA: NA | Gonorrheal vaginitis | NA | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | XDH; PTGS2; ABCC1; ABCC1 |
| C00-D49: Neoplasms | Pediatric cancer | C00-C96 | ADRA1D |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
| K00-K95: Diseases of the digestive system | Peptic ulcer | K25-K27 | ADRA2C |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | HTR1A; AR; OPRK1; OPRD1; ADRA1A; ACHE; ESR1; ADRA2C; ADRA2A; OPRM1; OPRM1; DRD2; PTGS2; PTGS2; PTGS2; PTGS2; PKM; HTR2C; SLC6A4 |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | FLT3; PTGS2 |
| K00-K95: Diseases of the digestive system | Pancreatitis | K85, K86.0K86.1 | HTR2A |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | HTR1A; MPO; ACHE; MAOA; DRD2; SLC6A4 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | HTR1A; ADRA1A; ACHE; MAPT; HTR6 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Chronic schizophrenics | F20 | HTR1B |
| C00-D49: Neoplasms | CLL | NA | FLT3 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cocaine addiction | F14.2 | DRD3 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | ADRA2A; DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sleep maintenance insomnia | F51.0, G47.0 | HTR2A |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | AR; ESR1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Hyperthermia | T68 | PTGS2 |
| K00-K95: Diseases of the digestive system | Diarrhea-predominant IBS | K58.0 | OPRK1; OPRD1 |
| A00-B99: Certain infectious and parasitic diseases | Diarrhea | A09, K59.1 | OPRM1; CFTR |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | DRD3; HTR2C |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | General anesthesia | R20.0 | OPRM1 |
| K00-K95: Diseases of the digestive system | Gastrointestinal problems | K30-K31, Q40-Q41 | DRD2 |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | ADRB3; OPRM1; OPRM1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Male hormonal deficiencies | E20-E35 | AR |
| C00-D49: Neoplasms | Overactive bladder disorder | C67, N32.81 | OPRD1; ADRB3 |
| C00-D49: Neoplasms | Osteosarcoma | C40-C41 | GSK3B |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis in post-menopausal women | M80-M81 | AR |
| C00-D49: Neoplasms | Ovarian cancer | C56 | ABCB1 |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MPO; ADRB2; ADRB2; ADRB2; ADRB3; DRD2 |
| NA: NA | Chronic low back pain | NA | SLC6A4 |
| NA: NA | Social phobia | NA | HTR1A |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | ABCB1; HIF1A; SYK; TP53; MAPK1; FLT3; PKM |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | AR; ESR1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cough | R05 | OPRD1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | AR; CFTR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Hypoactive sexual desire disorder | F52.0 | HTR1A |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53 |
| NA: NA | Heart block | NA | ADRB2 |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1 |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1 |
| NA: NA | Chemotherapyinduced emesis | NA | SLC6A4 |
| NA: NA | Chronic diarrhea associated with inflammatory bowel disease | NA | OPRD1 |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3 |
| G00-G99: Diseases of the nervous system G00-G99 | Acute migraine | G43 | OPRD1; HTR1D |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53; FLT3; FLT3 |
| NA: NA | Acute nonspecific diarrhea | NA | OPRD1 |
| C00-D49: Neoplasms | Breast cancer | C50 | AR; CYP19A1; FLT3; FLT3; ESR1; ESR1; DRD2 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Depressive fatigue | R53.82 | DRD2 |
| NA: NA | Depressive disorders | NA | SLC6A4 |
| K00-K95: Diseases of the digestive system | Dermal necrosis | K05 | DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Dementia | F01-F07 | HTR6 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | HTR1A; HTR2A; ADRA2C; MAOA; HTR2B; HTR2C; SLC6A4; SLC6A4; SLC6A4 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | GSK3B; ADRA1D; HTR2A; ADRB3; HTR2C |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | AR |
| G00-G99: Diseases of the nervous system G00-G99 | Headache | G43-G44, R51 | OPRM1 |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | ADRA2C; ADRB2 |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Opiate dependence | F11 | OPRK1; OPRM1 |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | HTR2A; MAPT |
| NA: NA | Cervical dystonia | NA | HTR1A |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | ADORA3; DRD2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | TTR |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Analgesia | R52, G89 | OPRM1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Anesthesia | R20.0 | OPRM1 |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA; HTR1D |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Erectile dysfunction | F52.2, N48.4 | ADRA1D |
| L00-L99: Diseases of the skin and subcutaneous tissue | Erythema | L51-L54 | OPRK1; ADRA2C |
| K00-K95: Diseases of the digestive system | Colon polyps | K63.5 | PTGS2 |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | ADORA3; CYP2D6 |
| I00-I99: Diseases of the circulatory system | Maintain blood pressure in hypotensive states | I10 | DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depression | F32, F33 | SLC6A4 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | HTR1A; HTR1A; OPRD1; HTR7; ADRA1A; ADRB3; ADRB3; OPRM1; MAOA; MAOA; HTR1B; DRD2; HTR1D; HTR2C; HTR2C; SLC6A4; SLC6A4 |
| C00-D49: Neoplasms | Non-hodgkin's lymphoma | C85 | SYK |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | SLC6A4 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | PTGS2; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2 |
| K00-K95: Diseases of the digestive system | Opioid-induced constipation | K59.0 | OPRM1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Eating disorder | E66, F50, I10-I16, I50 | HTR1A |
| NA: NA | Anxiety disorders | NA | HTR1A |
| I00-I99: Diseases of the circulatory system | Angina pectoris | I20 | ADRB3; DRD2 |
| NA: NA | Exacerbations of acute asthma | NA | ADRB2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1 |
| O00-O9A: Pregnancy, childbirth and the puerperium | Postpartum haemorrhage | O72 | DRD2 |
| NA: NA | Menopausal staging | NA | SLC6A4 |
| NA: NA | Menopausal disorder | NA | ESR1 |
| NA: NA | Malignant phaeochromocytoma | NA | DRD2 |
| NA: NA | Malignant essential hypertension | NA | DRD2 |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | ADRA2B; MAOA; PTGS2; PTGS2; SLC6A4; SLC6A4 |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1; ADRA2C; HTR2C; HTR6 |
| N00-N99: Diseases of the genitourinary system | Neurogenic bladder dysfunction | N31.9 | ADRB2 |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | OPRK1; ACHE; MAPT; HTR6 |
| I00-I99: Diseases of the circulatory system | Hypotension | I95 | ADRA2C; DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | OPRK1; OPRD1; HTR2A; ADRA2C; ADRA2B; MAOA; DRD2; HTR2C |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Advanced stage Parkinson's disease | F02.3, G20 | DRD2 |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Aging skin | L00-L99 | ADRB2 |
| C00-D49: Neoplasms | Aggressive non-hodgkin's lymphoma | C81, C81-C86, C82-C85, C91-C95 | HTR2C |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | HTR2C |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; ESR1 |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1 |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | AR |
| I00-I99: Diseases of the circulatory system | Cerebral infarction | I63 | HTR2B |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Narcotic depression | F19.20, F32 | OPRM1 |
| J00-J99: Diseases of the respiratory system | Nasal congestion | J34.89 | DRD2 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | SYK; DRD2 |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | HTR1A; HTR1A; GSK3B; ACHE; ACHE; ACHE; ADRA2C; MAOA; DRD2; PTGS2; MAPT; HTR6; HTR6; HTR6 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Nausea | R11 | HTR3A; HTR3A; DRD2 |
| NA: NA | Hyperaemia | NA | DRD2 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Emesis | R11 | HTR3A; DRD2; DRD3; HTR6 |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle atrophy | M62.5 | AR |
| C00-D49: Neoplasms | Female androgenresponsive recurrent mammary cancer | C50 | AR |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | HTR1A; HTR2A; OPRM1; HTR1D; HTR2B; HTR1F; CYP2D6; SLC6A4 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine headaches | G43 | HTR1B; DRD2; HTR1D; HTR2C |
| L00-L99: Diseases of the skin and subcutaneous tissue | Alopecia | L65.9 | AR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
| C00-D49: Neoplasms | Myeloma | C90 | SLC6A1 |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
| N00-N99: Diseases of the genitourinary system | Urinary incontinence | N39.3, N39.4, R32 | HTR1A; OPRD1; ADRA1D; ADRA1A; ADRB3; OPRM1 |
| NA: NA | Upper abdominal bloating | NA | ACHE |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1 |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Idiopathic thrombocytopenic purpura | D69.3 | DRD2 |
| A00-B99: Certain infectious and parasitic diseases | Infections disease | A00-B99 | MPO |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ADORA3; PTGS2 |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | OPRK1; DRD2; PTGS2 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | SYK; MPO; OPRM1; DRD2; PTGS2; SLC6A4 |
| NA: NA | Inflammatory diseases | NA | DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | DRD2; CYP2D6 |
| G00-G99: Diseases of the nervous system G00-G99 | Lateral sclerosis | G12.2 | HTR1A |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | ADRB3; ADRB3; ADRB3; PTGS2 |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| E00-E89: Endocrine, nutritional and metabolic diseases | TTR amyloidosis | E85 | TTR |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | AR; ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| NA: NA | Itching | NA | DRD2 |
| I00-I99: Diseases of the circulatory system | Ischemic heart diseases | I20-I25 | OPRD1 |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | ADORA3 |
| A00-B99: Certain infectious and parasitic diseases | Irritable bowel syndrome | A09, K58, K59.1 | HTR3A; ADRB3; HTR2B |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1 |
| C00-D49: Neoplasms | AML | NA | FLT3 |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ADRA2C |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | SYK; SYK; ADRA2C; ADRB2; ADRB2; ADRB2; ADRB3; ADRB3; OPRM1; DRD2; PTGS2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PTGS2; PTGS2; ABCC1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1 |
| NA: NA | Appetite suppressant | NA | SLC6A4 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychosis | F20-F29 | DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychoses | F20-F29 | HTR2B |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Fecal incontinence | R15 | ADRA1D |
| NA: NA | False perceptions | NA | DRD2 |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1 |
| NA: NA | Vomiting | NA | HTR3A; DRD2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Knee osteoarthritis | M15-M19, M47 | PTGS2 |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; ESR1 |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
| C00-D49: Neoplasms | Refractory renal cell carcinoma | C64 | PKM |
| H00-H59: Diseases of the eye and adnexa | Ocular disease | H00-H59 | ADRA2C |
| H00-H59: Diseases of the eye and adnexa | Ophthalmic disease | H00-H59 | DRD2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Endocrine disease | E00-E35 | AR |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | ABCB1; DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | ADRA2A; SLC6A4 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | DRD2 |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | RAB9A |
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | HTR3A; HTR2A; ADRA2C; SLC6A4; SLC6A4 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | HTR1A; ADRA1A; ESR1; DRD3 |
| N00-N99: Diseases of the genitourinary system | Vasomotor symptoms | N95.1 | SLC6A4 |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Severe mood disorders | F30-F39 | HTR1A; HTR1A; ADRB3; HTR1D |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Local anaesthetic | R20.0 | HTR3A |
| C00-D49: Neoplasms | Metastatic prostate cancer | C61 | AR |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Mild pain | R52, G89 | OPRM1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | SYK; ESR1 |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1 |
| NA: NA | Corneal vascularity | NA | DRD2 |
| I00-I99: Diseases of the circulatory system | Coronary artery disease | I20-I25 | HTR1A |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Convulsions | R56.0 | SLC6A1 |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | AR; ESR1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Contusion | S36.220S | ADRA2C |
| I00-I99: Diseases of the circulatory system | Coronary heart disease | I25.1 | HTR2B |
| N00-N99: Diseases of the genitourinary system | Stress urinary incontinence | N39.3 | ADRA1A |
| I00-I99: Diseases of the circulatory system | Cardiotonic | I50 | DRD2 |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
| I00-I99: Diseases of the circulatory system | Congestive heart failure | I50 | ADRA1D; HTR2B |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3 |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53; FLT3 |
| K00-K95: Diseases of the digestive system | Constipation | K59.0 | OPRM1 |
| K00-K95: Diseases of the digestive system | Gastric motility disorder | K22.4 | DRD3 |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Testosterone deficiency | E29.1 | AR |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | SYK |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; PTGS2 |
| NA: NA | Episode | NA | HTR1A |
| L00-L99: Diseases of the skin and subcutaneous tissue | Skin infections | L00-L99 | ADRB2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sleep disorders | F51, G47 | HTR7; HTR2A |
| NA: NA | Sleep initiation and maintenance disorders | NA | HTR2C |
| NA: NA | Postmenopausal disorder | NA | ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Post-traumatic stress disorder | F43.1 | ADRA1A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Premature ejaculation | F52.4 | HTR1A; OPRD1; ADRB2; SLC6A4 |
| N00-N99: Diseases of the genitourinary system | Bladder disease | N30-N32 | OPRD1 |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1; PTGS2; PTGS2; PTGS2; PTGS2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Substance dependence | F10-F19 | OPRK1; DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Smoking cessation | F17.2 | SLC6A4 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Spasm | R25.2 | HTR1A |
| I00-I99: Diseases of the circulatory system | Peripheral vascular disease | I73.9 | ADRA1D |
| NA: NA | Peripheral vasoconstriction | NA | DRD2 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; ADRA2C |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | ADRA2C; DRD3 |
| NA: NA | Male hypogonadism | NA | AR |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | ADORA3 |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
| NA: NA | Joint and muscular pain | NA | PTGS2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | HTR1A; HTR2A; MAOA; HTR1B; HTR1D; HTR2C; SLC6A4 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Moderate to severe rheumatoid arthritis | M05-M06 | PTGS2 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Moderate-to-severe pain | R52, G89 | OPRD1 |
| NA: NA | Schizoaffective disorder | NA | HTR1A |
| NA: NA | Schizoaffective disorders | NA | DRD2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | SYK; OPRD1; PTGS2; PTGS2; PTGS2; PTGS2 |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | ABCB1; OPRM1; DRD2; PTGS2 |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SYK; TP53 |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | AR; HTR2A |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | MPO; ESR1; ESR1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Movement disorder | R25 | OPRM1 |
| NA: NA | Myalgia | NA | SLC6A4 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | HTR1A; HTR1A; HTR7; HTR2A; HTR2A; DRD2; DRD2; DRD2; DRD2; DRD3; HTR2C; SLC6A4; HTR6 |
| NA: NA | Rheumatold arthritis | NA | PTGS2; PTGS2; PTGS2 |
| NA: NA | Peripheral sensory neuropathies | NA | HTR1A |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | AR; ESR1; ESR1 |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | AR; ESR1 |
| A00-B99: Certain infectious and parasitic diseases | HIV-associated diarrhoea | A09 | CFTR |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Erythropoietic porphyria | E80.0 | HTR2A |
| I00-I99: Diseases of the circulatory system | Cardiomyopathy | I42.0 | TTR |
| I00-I99: Diseases of the circulatory system | Cardiac failure | I50 | DRD2 |
| C00-D49: Neoplasms | Castration-resistant prostate cancer | C61 | AR |
| I00-I99: Diseases of the circulatory system | Pulmonary hypertension | I27.0, I27.2 | DRD2 |
| NA: NA | Hepatitis C virus infection | NA | ADORA3 |
| I00-I99: Diseases of the circulatory system | Hemorrhoids | I84 | HTR2A |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | AR; AR; ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Acromegaly | E22.0 | DRD2 |
| J00-J99: Diseases of the respiratory system | Acute asthma | J45 | ADRB2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Generalized anxiety disorder | F32, F40-F42, F41.1 | HTR1A; HTR1A; HTR2C |
| K00-K95: Diseases of the digestive system | Gastroesophageal reflux disease | K21 | HTR3A |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | AR; XDH; ADRA2C |
| NA: NA | Bulimia nervosa | NA | HTR1A |
| J00-J99: Diseases of the respiratory system | Bronchodilator | J45 | ADRB2 |
| J00-J99: Diseases of the respiratory system | Bronchitis | J20-J21, J42 | DRD2 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cancer pain | R52, G89 | OPRM1 |
| C00-D49: Neoplasms | Cancer | C00-C96 | ABCB1; AR; GSK3B; HIF1A; SYK; TP53; ADORA3; MAPK1; FLT3; FLT3; ACHE; ESR1; ESR1; PTGS2; SLC6A4; CSNK2A1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | AR; ADRB2 |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Carcinoid syndrome | E34.0 | DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | HTR1A; OPRD1; HTR2A; ACHE; CYP3A4; MAOA; HTR1B; DRD2; HTR2C; HTR6; HTR6 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Ankylosing spondylitis | M08.1, M45 | PTGS2 |